4 Green Flags for AbbVie in 2021

Given that AbbVie (NYSE: ABBV) is one of the largest pharma companies in the world, one might expect that it has a limited number of opportunities to deliver substantial growth to its investors. While it's true that the company will face headwinds once its best-selling drug Humira starts facing serious competition from generics in the U.S., AbbVie is intent on making the transition as smooth as possible for investors. Before the end of 2021, AbbVie may have five approvals or expanded indications for several of its drugs.